YNYou Ni

You Ni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


You Ni has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Qinming Zhou

    2 shared publications
  • Shengdi Chen

    Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    2 shared publications
  • Chen Ding

    Clinical Research Center for Cell‐based Immunotherapy of Shanghai Pudong Hospital, State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute Fudan University Shanghai China

    1 shared publication
  • Dingding Shen

    Department of Neurology, Affiliated Hospital of Nantong University, Medical School, Nantong University, Nantong, China

    1 shared publication
  • Dong Lv

    Department of Psychiatry Affiliated Hospital of Guangdong Medical University Zhanjiang China

    1 shared publication
  • Dou Yin

    Department of Neurology Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China

    1 shared publication

Latest Publications

  • Assessing Plasma APLP1 for the Progression of Parkinson's Disease: Insights from HSPD and PPMI Cohorts

    by You Ni, Ya‐Nan Yin, Wen‐Bo Yu, Yi‐Qi Liu, Jue Zhao, Yu‐Chen Yan, Wan‐Bing Zhao, Yi‐Lin Tang, Yi‐Min Sun, Feng‐Tao Liu, et al.

    Background: Amyloid precursor‐like protein 1 (APLP1) is involved in pathological α‐synuclein transmission, but its role in Parkinson's disease (PD) progression has not been explored.Objective: This study investigates APLP1 as a potential predictor for motor and cognitive deterioration in PD.Methods: Plasma APLP1 levels were measured in PD patients from the Huashan Hospital for Parkinson's Disease (HSPD) and Parkinson's Disease Progression Markers Initiative (PPMI) cohorts. A total of 916 participants were recruited in the HSPD cohort, and 171 participants were in the PPMI cohort. Longitudinal analysis examined the association between baseline APLP1 levels and PD progression.Results: A significant increase in APLP1 levels was observed in PD patients compared to healthy controls. Longitudinal analysis showed that patients with elevated baseline APLP1 levels experienced faster motor deterioration in HSPD cohort (HR = 3.627, P < 0.0001).Conclusions: The data indicate that APLP1 is associated with the progression of PD, potentially offering a measurable indicator of disease progression. © 2025 International Parkinson and Movement Disorder Society.


  • The clinical and neuroimaging features of sporadic adult-onset neuronal intranuclear inclusion disease

    by You Ni, Zhao Yang, Qinming Zhou, Jun Liu, Haiyan Zhou, Sheng Chen

    Background: Neuronal intranuclear inclusion disease (NIID) is a rare slowly progressive neurodegenerative disorder that is characterized pathologically by the presence of eosinophilic intranuclear inclusions. NIID is a heterogeneous disease with diverse clinical manifestations, making diagnosis difficult. Here, we analyzed the clinical, pathological, and radiological features of Chinese NIID patients to improve our understanding of NIID.Methods: A total of 17 patients with sporadic NIID were recruited from the Ruijin Hospital Database between 2014 and 2021. Clinical patient information and brain MRI data were collected. All of the patients underwent standard skin biopsy procedures.Results: The average age of onset for symptoms was 60.18 years, and the average duration of illness was 4.06 years. All patients were diagnosed with NIID due to the presence of intranuclear inclusions confirmed by skin biopsy. Tremor was the most common initial symptom. The average ages at onset and at diagnosis were both lower in patients with tremor than in patients without tremor. NIID may be a systemic disease that affects multiple organs, for one patient had a history of chronic renal insufficiency for more than 10 years. In addition to high-intensity U-fibers signals on diffusion-weighted imaging, there were several other MRI findings, such as focal leukoencephalopathy and cortical swelling. Encephalitic episodes followed by reversible leukoencephalopathy was another important imaging feature of NIID.Conclusion: The clinical manifestations of NIID are highly variable. Tremor may be the most common initial symptom in certain cohorts. Encephalitic episodes followed by reversible asymmetric leukoencephalopathy may also indicate this disease.


  • Expanding the clinical spectrum of anti‐IgLON5 disease: A multicenter retrospective study

    by You Ni, Dingding Shen, Ying Zhang, Yaying Song, Yining Gao, Qinming Zhou, Lu He, Dou Yin, Ying Wang, Fan Song, et al.

    Background: We conducted this study to describe detailed the clinical characteristics, ancillary test results and treatment response of a group of Chinese patients with anti‐IgLON5 disease.Methods: We recruited 13 patients with positive IgLON5 antibodies in serum and/or cerebrospinal fluid from nine tertiary referral centers. Patients were enrolled from February 2017 to July 2021. We retrospectively collected information on the presenting and main symptoms, treatment response and follow‐up outcomes.Results: The median age of onset for symptoms was 60 (range: 33–73) years and six of the 13 patients were females. The predominant clinical presentations included sleep disturbance (eight patients) and cognitive impairment (seven patients), followed by movement disorders (six patients). Parainfectious cause seemed plausible. Notably, we identified the first case of possible Epstein‐Barr virus (EBV)‐related anti‐IgLON5 disease. Coexisting neural autoantibodies were identified in two patients. Furthermore, two patients had other autoimmune diseases. The IgG subclass was determined in four patients, including two with dominant IgG4 subtype and two with dominant IgG1 subtype. Additionally, 10 patients were treated with immunotherapy and four patients exhibited improvement. Overall, six of 10 patients for whom follow‐up results were assessable had favorable clinical outcomes (modified Rankin Scale score ≤2).Conclusions: The clinical spectrum of anti‐IgLON5 disease is variable. Our results highlight a boarder spectrum of anti‐IgLON5 disease.